F.d.e.c.a Pharmaceutical Import Profile — Ecuador (DGFT 2022–2026)

Name: F.d.e.c.a Pharmaceutical Import Records from India — 2 Products, $380.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

F.d.e.c.a — Pharmaceutical Importer Profile (2026) | 2 Products, $380.6K Trade | TransData Nexus

F.d.e.c.a

Pharmaceutical Importer · Ecuador · Corticosteroids Focus · $380.6K Total Trade · DGFT Verified

F.d.e.c.a is a pharmaceutical importer based in Ecuador with a total trade value of $380.6K across 2 products in 2 therapeutic categories. Based on 9 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. F.d.e.c.a sources from 1 verified Indian supplier, with Caritas Healthcare Private Limited accounting for 100.0% of imports.

F.d.e.c.a — Import Portfolio & Supplier Network

F.d.e.c.a import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to F.d.e.c.a?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Caritas Healthcare Private Limited	$5.2M	227	100.0%

F.d.e.c.a sources from 1 verified Indian supplier across 175 distinct formulations. The sourcing is highly concentrated — Caritas Healthcare Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does F.d.e.c.a Import?

Formulation	Value	Ships
Pharmacuiticals finished product	$200.0K	4
Pharmacuiticals finished product	$150.0K	3
Finished pharamceutical product - tacrolimus capsual 1MG - tacrocord 1MG	$150.0K	3
Finished pharamceutical product-atorvastatin tablets 40MG b.no.egt250058	$125.4K	3
Pharmacuiticals finished product amphotericin b lipid complex injection intravenous (50MG/10ML)	$100.0K	2
Finished pharamceutical product -iron sucrose injection 100 MG/5 ML INJ batch nois25002e is25003e mfg date feb-25 exp	$100.0K	2
Finished pharamceutical product - carvedilol tablets 12.5MG batch no. emv250362emv250370 emv250371 emv250372a	$100.0K	2
Urea cream BP 5% w/w batch no.g2339,g2340,g2341,g2347,g2338,g2342,g2344,g2345,g2346	$68.8K	3
Finished pharamceutical product-carvedilol TAB USP 12.5MG b.no.emv232124 to	$67.1K	3
Finished pharamceutical product -rivaroxaban tablet 20MG b.no.emv250406b	$63.7K	3
Urea cream 5% w/w Pack style 1 x 1 tubebatch no. g2343 g2348 g2349 g2350 g2351g2353 g2354 g2355 g2356 mfg date	$61.8K	3
Finished pharamceutical product - voricanazole tablet 200MG batch no. gt2436 mfgdate mar-25 exp date	$59.4K	2
Finished pharamceutical product -voricanazole tablet 200MG	$57.1K	3
Finished pharamceutical product - atorvastatin tablets 40MG batch no. egt250059egt250060 mfg date feb-25 exp date	$52.4K	2
Pharmacuiticals finished product	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Methylprednisolone	Corticosteroids	$342.0K	7	1.2%	12
2	Digoxin	Cardiovascular	$38.7K	2	1.8%	7

F.d.e.c.a imports 2 pharmaceutical products across 2 categories into Ecuador totaling $380.6K.

F.d.e.c.a — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

F.d.e.c.a is a pharmaceutical importer based in Ecuador, specializing in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in the Ecuadorian pharmaceutical distribution network, ensuring the availability of essential medications to meet the country's healthcare needs. While specific details about its headquarters, parent company, and organizational structure are not publicly disclosed, F.d.e.c.a's operations are integral to the importation and distribution of pharmaceutical products within Ecuador.

2Distribution Network

F.d.e.c.a's distribution network encompasses multiple warehouse locations strategically situated across Ecuador to facilitate efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are tailored to meet the stringent requirements of the pharmaceutical industry, ensuring compliance with health regulations and maintaining the integrity of the products during transit. F.d.e.c.a's geographic coverage extends throughout Ecuador, enabling it to serve a wide range of healthcare facilities, including hospitals, clinics, and pharmacies, thereby contributing to the accessibility of quality medications nationwide.

3Industry Role

Within Ecuador's pharmaceutical supply chain, F.d.e.c.a functions primarily as a pharmaceutical importer and distributor. The company is responsible for sourcing finished pharmaceutical formulations from international suppliers, particularly from India, and ensuring their availability in the Ecuadorian market. By importing a diverse range of pharmaceutical products, F.d.e.c.a supports the healthcare sector by providing essential medications that might not be locally produced, thereby enhancing the overall healthcare delivery system in Ecuador.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — F.d.e.c.a

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

F.d.e.c.a's sourcing strategy exhibits a high degree of concentration, with a total import value of $381,000 USD from India over nine shipments, focusing on two primary products: Methylprednisolone and Digoxin. This concentrated sourcing approach indicates a strategic choice to establish a reliable supply chain with a single supplier, CARITAS HEALTHCARE PRIVATE LIMITED, which has been the sole supplier for all shipments. The consistent partnership with CARITAS HEALTHCARE PRIVATE LIMITED suggests a stable and dependable relationship, reducing the complexities associated with managing multiple suppliers. However, this single-source dependency also presents a potential risk; any disruptions in CARITAS HEALTHCARE PRIVATE LIMITED's operations could directly impact F.d.e.c.a's ability to meet market demand.

2Supply Chain Resilience

F.d.e.c.a's supply chain resilience is closely tied to its exclusive partnership with CARITAS HEALTHCARE PRIVATE LIMITED. The lack of backup suppliers means that any operational challenges faced by CARITAS HEALTHCARE PRIVATE LIMITED—such as production delays, quality control issues, or logistical disruptions—could significantly affect F.d.e.c.a's ability to supply products to the Ecuadorian market. The limited diversity in imported formulations, with only 175 unique formulations, further constrains the company's ability to adapt to changes in market demand or supply chain disruptions. Additionally, the reliance on a single supplier may expose F.d.e.c.a to risks related to geopolitical factors, regulatory changes, or economic conditions affecting CARITAS HEALTHCARE PRIVATE LIMITED's operations.

Importing Pharmaceuticals into Ecuador — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Ecuador

1Regulatory Authority & Framework

In Ecuador, the National Agency for Regulation, Control, and Sanitary Surveillance (ARCSA) is the primary regulatory body overseeing the pharmaceutical sector. ARCSA is responsible for ensuring that all pharmaceutical products, including those imported by companies like F.d.e.c.a, meet the required safety, efficacy, and quality standards. The regulatory framework governing pharmaceutical imports in Ecuador includes the Organic Law of Health, which outlines the requirements for the registration, control, and surveillance of medicines. Additionally, the Andean Community's regulations, to which Ecuador is a member, provide guidelines for the harmonization of pharmaceutical standards and facilitate the importation process within member countries.

2Import Licensing & GMP

Import licensing in Ecuador requires that all pharmaceutical products obtain a sanitary registration certificate from ARCSA before they can be legally imported and marketed. This process ensures that imported medicines comply with national health standards. Good Manufacturing Practices (GMP) certification is also mandatory for pharmaceutical products entering Ecuador. Ecuador recognizes GMP certificates from reputable international bodies, including the World Health Organization (WHO) and the European Union (EU). Importers like F.d.e.c.a must ensure that their suppliers hold valid GMP certifications from recognized authorities to facilitate the importation process and ensure product quality.

F.d.e.c.a — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

F.d.e.c.a's focus on importing corticosteroids and cardiovascular medications, specifically Methylprednisolone and Digoxin, indicates a strategic alignment with prevalent health conditions in Ecuador. Corticosteroids are commonly used to treat inflammatory and autoimmune disorders, while cardiovascular drugs are essential for managing heart-related conditions. The market demand for these therapeutic areas is driven by the high incidence of chronic diseases such as arthritis, asthma, hypertension, and heart failure in the Ecuadorian population. By concentrating on these categories, F.d.e.c.a addresses critical healthcare needs, ensuring the availability of vital medications to improve patient outcomes.

2Sourcing Profile

F.d.e.c.a's sourcing strategy is centered on importing generic drugs from India, focusing on specific formulations that align with the therapeutic needs of the Ecuadorian market. The company's preference for finished pharmaceutical formulations, rather than raw Active Pharmaceutical Ingredients (APIs), suggests a streamlined approach to procurement, emphasizing ready-to-use products that meet established quality standards. India's robust pharmaceutical manufacturing sector, known for its adherence to international GMP standards, positions it as a reliable source for high-quality generic medications. This sourcing strategy enables F.d.e.c.a to provide cost-effective and accessible treatment options to the Ecuadorian healthcare system.

Seller's Guide — How to Become a Supplier to F.d.e.c.a

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with F.d.e.c.a, especially given the company's concentrated sourcing strategy and reliance on a single supplier. Introducing alternative suppliers can help diversify F.d.e.c.a's supply chain, mitigating risks associated with single-source dependency. Potential gaps in F.d.e.c.a's current sourcing include a limited range of imported formulations and a lack of backup suppliers. By offering a broader portfolio of products and establishing reliable supply chains, new Indian suppliers can meet these needs, enhancing F.d.e.c.a's ability to serve the Ecuadorian market more effectively.

2Requirements & Qualifications

Indian exporters aiming to supply F.d.e.c.a and the Ecuadorian market must ensure that their products comply with Ecuador's regulatory requirements. This includes obtaining a sanitary registration certificate from ARCSA for each pharmaceutical product intended for importation. Additionally, products must adhere to Good Manufacturing Practices (GMP) recognized by international bodies such as the World Health Organization (WHO) and the European Union (EU). Labeling must be in Spanish, with all required information clearly presented. Furthermore, the implementation of a Unique Traceability Code (CUT) on packaging is mandatory to

Frequently Asked Questions — F.d.e.c.a

What products does F.d.e.c.a import from India?

F.d.e.c.a imports 2 pharmaceutical products across 2 categories. Top imports: Methylprednisolone ($342.0K), Digoxin ($38.7K).

Who supplies pharmaceuticals to F.d.e.c.a from India?

F.d.e.c.a sources from 1 verified Indian suppliers. The primary supplier is Caritas Healthcare Private Limited (100.0% of imports, $5.2M).

What is F.d.e.c.a's total pharmaceutical import value?

F.d.e.c.a's total pharmaceutical import value from India is $380.6K, based on 9 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does F.d.e.c.a focus on?

F.d.e.c.a imports across 2 categories. The largest: Corticosteroids (89.8%), Cardiovascular (10.2%).

Get Full F.d.e.c.a Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.